Kalaris Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$46.2M | -$51.7M | -$199.9M | -$171.2M | -$169.8M |
| Operating expenses | $46.2M | $51.7M | $199.9M | $171.2M | $169.8M |
| Cash from operations | -$38.4M | -$20.7M | -$124.5M | -$142.1M | -$106.3M |
| Capital expenditure | $200,000 | — | — | — | $26,000 |
| Free cash flow | -$38.6M | — | — | — | -$106.3M |
| Share repurchases | — | $32,000 | — | — | — |
| Impairments | — | $0 | $18.6M | $0 | $0 |
| Total assets | $121.7M | $6.2M | $190.8M | $277.1M | $286.6M |
| Total liabilities | $42.9M | $56.8M | $45.0M | $52.6M | $61.3M |
Shares outstanding 23.8M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.